Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.41 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.41 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.41 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8198455 | 0.83 | EGLN2 (0.71) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| SCHEMBL4752202 | 0.78 | EGLN2 (0.60) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| SCHEMBL2570669 | 0.71 | EGLN2 (0.72) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| Hydrochloric Acid SCHEMBL3706626 | 0.70 | EGLN2 (0.71) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| SCHEMBL3708665 | 0.70 | EGLN2 (0.64) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| Hydrochloric Acid SCHEMBL3708662 | 0.69 | EGLN2 (0.63) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| SCHEMBL4752172 | 0.69 | EGLN2 (0.73) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| SCHEMBL15445844 | 0.69 | EGLN2 (0.69) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| SCHEMBL2573299 | 0.68 | EGLN2 (1.00) | EGLN2EGLN1P4HTMTET2OGFOD1 | |
| SCHEMBL3710480 | 0.68 | EGLN1 (0.60) | EGLN2EGLN1P4HTMTET2OGFOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389520-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389520-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, HPGDS | EGLN2 44/4885EGLN1 219/4885P4HTM 644/4885 |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | EGLN2 250/4885EGLN1 828/4885P4HTM 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.